title: Early hypertension and prolonged mineralocorticoid therapy discontinuation in a child with salt-wasting 21-hydroxylase deficiency.
authors.forename: M
authors.initials: M
authors.lastname: Wasniewska
authors.forename: M
authors.initials: M
authors.lastname: Valenzise
authors.forename: T
authors.initials: T
authors.lastname: Aversa
authors.forename: S
authors.initials: S
authors.lastname: Mirabelli
authors.forename: F
authors.initials: F
authors.lastname: De Luca
authors.forename: F L
authors.initials: FL
authors.lastname: De Luca
authors.forename: F
authors.initials: F
authors.lastname: Lombardo
mesh_terms: D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy* / Q000503:physiopathology; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D002675:Child, Preschool; D005438:Fludrocortisone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000627:therapeutic use; D006973:Hypertension / Q000209:etiology*; D007231:Infant, Newborn; D008297:Male; D008901:Mineralocorticoids / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D008901:Mineralocorticoids; D005438:Fludrocortisone; C034635:fludrocortisone acetate; D006854:Hydrocortisone